Park Avenue Securities LLC increased its position in shares of AstraZeneca PLC (NASDAQ:AZN - Free Report) by 15.1% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 88,980 shares of the company's stock after acquiring an additional 11,668 shares during the period. Park Avenue Securities LLC's holdings in AstraZeneca were worth $6,540,000 as of its most recent filing with the Securities and Exchange Commission.
Other large investors have also made changes to their positions in the company. Capital International Investors boosted its position in AstraZeneca by 1.9% in the fourth quarter. Capital International Investors now owns 37,507,159 shares of the company's stock valued at $2,457,706,000 after buying an additional 686,008 shares in the last quarter. Bank of America Corp DE boosted its position in AstraZeneca by 189.3% in the fourth quarter. Bank of America Corp DE now owns 24,026,966 shares of the company's stock valued at $1,574,247,000 after buying an additional 15,722,197 shares in the last quarter. Franklin Resources Inc. boosted its position in AstraZeneca by 1.9% in the fourth quarter. Franklin Resources Inc. now owns 19,480,569 shares of the company's stock valued at $1,276,367,000 after buying an additional 357,894 shares in the last quarter. Sanders Capital LLC boosted its position in AstraZeneca by 1.4% in the fourth quarter. Sanders Capital LLC now owns 15,186,692 shares of the company's stock valued at $995,032,000 after buying an additional 212,301 shares in the last quarter. Finally, Fisher Asset Management LLC boosted its position in AstraZeneca by 4.6% in the fourth quarter. Fisher Asset Management LLC now owns 10,959,852 shares of the company's stock valued at $718,090,000 after buying an additional 479,692 shares in the last quarter. Institutional investors and hedge funds own 20.35% of the company's stock.
Wall Street Analyst Weigh In
A number of brokerages have weighed in on AZN. Morgan Stanley began coverage on shares of AstraZeneca in a research report on Wednesday, February 12th. They issued an "overweight" rating on the stock. UBS Group upgraded shares of AstraZeneca from a "neutral" rating to a "buy" rating in a report on Thursday, February 13th. Finally, BNP Paribas began coverage on shares of AstraZeneca in a report on Tuesday, April 15th. They set an "outperform" rating and a $75.00 price target on the stock. One equities research analyst has rated the stock with a hold rating, five have issued a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat, AstraZeneca has a consensus rating of "Buy" and a consensus price target of $85.00.
Check Out Our Latest Stock Analysis on AZN
AstraZeneca Price Performance
Shares of NASDAQ:AZN opened at $72.88 on Monday. The firm has a market cap of $226.02 billion, a PE ratio of 32.25, a price-to-earnings-growth ratio of 1.42 and a beta of 0.38. The firm's fifty day moving average is $69.32 and its 200-day moving average is $70.05. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.74 and a current ratio of 0.93. AstraZeneca PLC has a 52 week low of $61.24 and a 52 week high of $87.68.
AstraZeneca (NASDAQ:AZN - Get Free Report) last released its earnings results on Tuesday, April 29th. The company reported $1.24 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.10 by $0.14. The business had revenue of $13.59 billion for the quarter, compared to analyst estimates of $13.71 billion. AstraZeneca had a net margin of 13.01% and a return on equity of 32.23%. AstraZeneca's revenue for the quarter was up 7.2% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.06 earnings per share. Sell-side analysts predict that AstraZeneca PLC will post 4.51 earnings per share for the current year.
AstraZeneca Profile
(
Free Report)
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.
Further Reading
Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca PLC (NASDAQ:AZN - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider AstraZeneca, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AstraZeneca wasn't on the list.
While AstraZeneca currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
